Forecast

The analysts' average price target is €41.86 (+62.94%). The median is €41.86 (+62.94%).

Buy	5
Hold	0
Sell	0

News Go to news feed

Electromed beats earnings expectations for Q4, stock weighed down by slight revenue miss and CEO resignation

Electromed reported diluted earnings per share of $0.39 for Q4, beating the $0.31 estimate, while revenue of $19.41 million narrowly missed projections. Fiscal 2026 marked the 15th consecutive quarter of revenue and earnings growth; annual revenue rose to $73.8 million and gross margin improved to 78.5%. The stock fell about 3.5% after the report as investors reacted to the revenue shortfall, a 29% decline in hospital revenue and the announced CEO resignation in April 2027. Management forecasts double‑digit revenue growth for 2027, continued operating leverage, and plans to expand sales and pursue further operational initiatives. » More on de.investing.com
Electromed: CEO Jim Cunniff to retire on April 2, 2027

Jim Cunniff, president and CEO of Electromed, announced that he will retire on April 2, 2027 and will resign his seat on the board of directors. The board has engaged an executive search firm to conduct a nationwide search for his successor. Cunniff has held his current position since 2023; Electromed manufactures, among other products, the SmartVest Airway Clearance System. » More on de.investing.com
Electromed expects quarterly results with rising revenue and earnings estimates

Electromed will open the books for the quarter ended June 30, 2026 on August 25, 2026. Three analysts forecast on average an EPS of $0.317 (prior year $0.250) and revenues of around $19.3 million (+11.2% versus $17.4 million). For the just-ended fiscal year, the consensus is earnings per share of $1.22 (previously $0.85) and revenue of about $73.6 million (prior year $64.0 million). » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2022, ELECTROMED INC. DL -,001 has already paid €1.14 in dividends. The last payout was in April 2022.

Financials

In the last quarter, ELECTROMED INC. DL -,001 had revenue of €17.01M and net profit of €2.98M

(EUR)	Jun 2026	YoY
Revenue	17.01M	15.29%
Gross profit	13.39M	15.86%
Net profit	2.98M	59.36%
EBITDA	3.59M	18.45%

Fundamentals

Metric	Value
Market capitalization	€215.4M
Number of shares	8.28M
52-week high/low	€40.91 - €19.86
Dividends	No
Beta	0.51
P/E ratio	22.00
PEG ratio	0.40
P/B ratio	4.62
P/S ratio	3.38

Company profile

Electromed, Inc. entwickelt, produziert, vermarktet und verkauft Atemwegstherapien und verwandte Produkte, die Hochfrequenz-Brustwand-Oszillationstherapie (HFCWO) in der pulmonalen Versorgung von Patienten verschiedenen Alters in den Vereinigten Staaten und international anwenden. Das Unternehmen bietet das SmartVest Airway Clearance System, das SmartVest SQL System, das aus einem aufblasbaren Therapiekleidungsstück, einem programmierbaren Luftimpulsgenerator und einem patentierten Einzelschlauch besteht, der Luftimpulse vom Generator zum Kleidungsstück liefert, sowie SmartVest Connect, eine drahtlose Technologie mit personalisiertem HFCWO-Therapiemanagementportal für Patienten mit eingeschränkter Lungenfunktion. Darüber hinaus bietet das Unternehmen SmartVest- und SmartVest Wrap-Produkte für den Einmalgebrauch für Gesundheitsdienstleister in der Akutversorgung an. Das Unternehmen bietet seine Produkte vor allem in der häuslichen Pflege für Patienten mit Bronchiektasen, zystischer Fibrose und neuromuskulären Erkrankungen an. Electromed, Inc. vertreibt seine Produkte hauptsächlich an Ärzte und Gesundheitsdienstleister sowie direkt an Patienten. Das Unternehmen wurde 1992 gegründet und hat seinen Hauptsitz in New Prague, Minnesota.

Name	ELECTROMED INC. DL -,001
CEO	James L. Cunniff
Headquarters	New Prague, mn USA
Website	smartvest.com
Sector	Health Care
Industry	Health Care Equipment & Supplies
IPO	08/13/2010
Employees	195